Nu.Q H3.1
Determine levels of H3.1-containing, circulating cell-free nucleosomes
Nucleosomes: The Next Generation of Cancer Biomarkers
A nucleosome, composed of histone proteins and the DNA wrapped around them, is the core unit of chromatin. The affect nucleosomes have on chromatin structure and gene regulation is dependent upon the identity of the histones that make up the nucleosome, as well as any modifications to these histone proteins. With a plethora of histone protein variants and post-translational modifications that can occur on their “histone tails”, there are a vast number of possibilities when it comes to the exact identiity of a nucleosome and its function. Recently, some of these variants and modifications have been found to associate with cancers. Furthermore, just the total amount of nucleosomes detected can also indicate a disease state or correlate with efficacy of therapy.
Recently, “liquid biopsies”, or blood draws from which you can examine biomarkers, have taken hold as an easy, less invasive method to monitor disease state and treatment efficacy. Nucleosomes, histones, and DNA can be shed into the blood during cancer due to high cellular turnover or in response to chemotherapy. Free-floating DNA (cfDNA and ctDNA) is an attractive biomarker, but has shown to be less stable than nucleosomes. Additionally, next generation sequencing of DNA is cumbersome and costly compared to a high-throughput ELISA assay to detect intact nucleosomes. Nucleosome-specific detection assays represent a new generation of biomarker tests: easy, fast, cost-effective, and compatible with stable proteins in liquid biopsy samples.
Histone H3.1
Active Motif’s Nu.Q H3.1 Assay Kit is designed for the detection of levels of Histone H3.1-containing, circulating cell-free nucleosomes (cf-nucleosomes) in human serum in a high-throughput format. Histone H3.1, or the canonical form of Histone H3, is deposited during DNA replication and possibly also during repair. Study of H3.1 has identified cancer-associated mutations and differing affinities for the histone acetyltransferase HAT1. To examine H3-containing nucleosome for all variants, use our Nu.Q H3 Assay. For added convenience and a more quantitative interpretation of results, the Nu.Q H3.1 Assay Kit also includes a recombinant nucleosome protein for use as a reference standard curve. For complete details, click the Nu.Q Method tab below.
Why use Nu.Q H3.1?
- Sensitivity: Detect circulating nucleosomes in as little as 10 µl of serum or 20 µl of plasma
- Specificity: Nucleosome epitope specific antibody enables detection of only intact nucleosomes
- Quantification: Recombinant nucleosomes enable relative quantification of levels of circulating H3.1 nucleosomes
- Convenience: Colorimetric assay in a simple 96-stripwell format for high and low throughput
- Fast: Results can be obtained in 5 hoursA nucleosome, composed of histone proteins and the DNA wrapped around them, is the core unit of chromatin. The affect nucleosomes have on chromatin structure and gene regulation is dependent upon the identity of the histones that make up the nucleosome, as well as any modifications to these histone proteins. With a plethora of histone protein variants and post-translational modifications that can occur on their “histone tails”, there are a vast number of possibilities when it comes to the exact identiity of a nucleosome and its function. Recently, some of these variants and modifications have been found to associate with cancers. Furthermore, just the total amount of nucleosomes detected can also indicate a disease state or correlate with efficacy of therapy.
Recently, “liquid biopsies”, or blood draws from which you can examine biomarkers, have taken hold as an easy, less invasive method to monitor disease state and treatment efficacy. Nucleosomes, histones, and DNA can be shed into the blood during cancer due to high cellular turnover or in response to chemotherapy. Free-floating DNA (cfDNA and ctDNA) is an attractive biomarker, but has shown to be less stable than nucleosomes. Additionally, next generation sequencing of DNA is cumbersome and costly compared to a high-throughput ELISA assay to detect intact nucleosomes. Nucleosome-specific detection assays represent a new generation of biomarker tests: easy, fast, cost-effective, and compatible with stable proteins in liquid biopsy samples.
Histone H3 Phosphorylation Antibody Panel Pack |
|||
| C10014 | EpiGentek |
|
|
Histone H3 Acetylation Antibody Panel Pack I |
|||
| C10010 | EpiGentek |
|
|
Histone H3 Acetylation Antibody Panel Pack II |
|||
| C10011 | EpiGentek |
|
|
Histone H3 Methylation Antibody Panel Pack I – Active Genes |
|||
| C10000 | EpiGentek |
|
|
Histone H3 Methylation Antibody Panel Pack I – Repression Genes |
|||
| C10001 | EpiGentek |
|
|
Histone H3 Methylation Antibody Panel Pack II – Active Genes |
|||
| C10002 | EpiGentek |
|
|
Histone H3 Methylation Antibody Panel Pack II – Repression Genes |
|||
| C10003 | EpiGentek |
|
|
Histone H3 Methylation Antibody Panel Pack III – Active Genes |
|||
| C10004 | EpiGentek |
|
|
Tertiapin-Q |
|||
| B5090-1 | ApexBio | 1 mg | EUR 656.4 |
NU 9056 |
|||
| A4492-10 | ApexBio | 10 mg | EUR 340.8 |
|
Description: Selective KAT5 (Tip60) histone acetyltransferase inhibitor (IC50 values are 100 ?M for KAT5, p300, pCAF and GCN5, respectively). Inhibits protein acetylation in prostate cancer cell lines and blocks DNA damage response. |
|||
NU 1025 |
|||
| A4530-25 | ApexBio | 25 mg | EUR 528 |
|
Description: Novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP). Ki and IC50 values are 48 and 400 nM respectively. |
|||
NU 1025 |
|||
| A4530-5 | ApexBio | 5 mg | EUR 216 |
|
Description: Novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP). Ki and IC50 values are 48 and 400 nM respectively. |
|||
NU 1025 |
|||
| A4530-50 | ApexBio | 50 mg | EUR 945.6 |
|
Description: Novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP). Ki and IC50 values are 48 and 400 nM respectively. |
|||
NU 7026 |
|||
| A8649-10 | ApexBio | 10 mg | EUR 164.4 |
|
Description: NU 7026 is a selective inhibitor of DNA-PK with IC50 value of 0.23 ?M [1]. |
|||
NU 7026 |
|||
| A8649-50 | ApexBio | 50 mg | EUR 505.2 |
|
Description: NU 7026 is a selective inhibitor of DNA-PK with IC50 value of 0.23 ?M [1]. |
|||
Nu 6027 |
|||
| A1986-10 | ApexBio | 10 mg | EUR 211.2 |
|
Description: NU6027 is a potent inhibitor of cellular ATR activity with the IC50 of 6.7 ?M.The ataxia telangiectasia mutated and Rad3-related kinase (ATR) has a crucial role in the stalled replication forks signalling and DNA damage to cell cycle checkpoints and DNA repair. |
|||
Nu 6027 |
|||
| A1986-5 | ApexBio | 5 mg | EUR 154.8 |
|
Description: NU6027 is a potent inhibitor of cellular ATR activity with the IC50 of 6.7 ?M.The ataxia telangiectasia mutated and Rad3-related kinase (ATR) has a crucial role in the stalled replication forks signalling and DNA damage to cell cycle checkpoints and DNA repair. |
|||
Nu 6027 |
|||
| A1986-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 157.2 |
|
Description: NU6027 is a potent inhibitor of cellular ATR activity with the IC50 of 6.7 ?M.The ataxia telangiectasia mutated and Rad3-related kinase (ATR) has a crucial role in the stalled replication forks signalling and DNA damage to cell cycle checkpoints and DNA repair. |
|||
Nu 6027 |
|||
| A1986-50 | ApexBio | 50 mg | EUR 656.4 |
|
Description: NU6027 is a potent inhibitor of cellular ATR activity with the IC50 of 6.7 ?M.The ataxia telangiectasia mutated and Rad3-related kinase (ATR) has a crucial role in the stalled replication forks signalling and DNA damage to cell cycle checkpoints and DNA repair. |
|||
NU 7026 |
|||
| HY-15719 | MedChemExpress | 10mM/1mL | EUR 151.2 |
NU-7441 |
|||
| B1117-25 | Biovision | each | EUR 652.8 |
NU-7441 |
|||
| B1117-5 | Biovision | each | EUR 210 |
NU-7026 |
|||
| B2522-25 | Biovision | each | EUR 652.8 |
NU-7026 |
|||
| B2522-5 | Biovision | each | EUR 210 |
NU 1025 |
|||
| 2351-5 | Biovision | each | EUR 314.4 |
NU 7026 |
|||
| 27312 | BPS Bioscience | 50 mg | EUR 525 |
|
Description: PARP3 Inhibitor |
|||
Q-VD-OPh |
|||
| 1170-1 | Biovision | each | EUR 280.8 |
anti-PKC nu (Protein kinase C nu) |
|||
| LF-PA0073 | Abfrontier | 100 ul | EUR 400.8 |
|
Description: Rabbit polyclonal to PKC nu (Protein kinase C nu) |
|||
Histone H3 |
|||
| 79055-1 | BPS Bioscience | 100 µg | EUR 70 |
|
Description: Human Histone 3 (HIST1H3E), GenBank Accession No. NM_003532, a.a. 1-136(end), MW = 15 kDa, expressed in an E. coli expression system. |
|||
LabTek 1 Well Permanox Slide RUO |
|||
| 177410K | Scientific Laboratory Supplies | PK16 | EUR 299.82 |
Q-VD(OMe)-OPh |
|||
| A8165-1 | ApexBio | 1 mg | EUR 212.4 |
|
Description: Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad spectrum caspase inhibitor, provides a cost effective, non toxic, and highly specific means of apoptotic inhibition and provides new insight into the design of new inhibitors. |
|||
Q-VD-OPh hydrate |
|||
| A1901-1 | ApexBio | 1 mg | EUR 212.4 |
|
Description: The broad spectrum caspase inhibitor, QVD-OPh, provides a cost effective, non toxic, and highly speci?c means of apoptotic inhibition and provides new insight into the design of new inhibitors1. |
|||
EZSolution? Q-VD-OPh |
|||
| 1173-1 | Biovision | each | EUR 248.4 |
EZSolution? Q-DEVD-OPh |
|||
| 1178-1 | Biovision | each | EUR 326.4 |
Q-VD(OMe)-OPh |
|||
| 27640-1 | BPS Bioscience | 5 mg | EUR 380 |
|
Description: Q-VD-(OMe)-Ph is a second-generation capase inhibitor that is highly potent, brain and cell permeable, irreversible and nontoxic. Q-VD-(OMe)-Ph can inhibit caspase-3 ( IC50=25 nm), caspase-1 (IC50=50 nM), caspase-8 (IC50=100 nM) and caspase-9 (IC50=430 nM). |
|||
EpiQuik DNA Methyltransferase (DNMT) Activity/Inhibition Assay Kit |
|||
| P-3001 | EpiGentek |
|
|
EpiQuik Histone Methyltransferase Activity/Inhibition Assay Kit (H3K4) |
|||
| P-3002 | EpiGentek |
|
|
EpiQuik Histone Methyltransferase Activity/Inhibition Assay Kit (H3K9) |
|||
| P-3003 | EpiGentek |
|
|
Protein Kinase C Nu Type (PKC nu) Antibody |
|||
| abx033122-400ul | Abbexa | 400 ul | EUR 627.6 |